| 13-HDPA | 13-hydroxyDPA |
| 13-HODE | 13-Hydroxyoctadecadienoic acid |
| 13-HpDPA | 13-hydroperoxyDPA |
| 15-HEPE | 15-hydroxyeicosapentaenoic acid |
| 15-HETE | 15-Hydroxyeicosatetraenoic acid |
| 17-R-HDHA | 17-R-hydroperoxyDHA |
| 18-HEPE | 18-hydroxyeicosapentaenoic acid |
| AA | Arachidonic acid; (20:4, n-6) |
| Akt | Protein kinase B (PKB) |
| Apaf-1 | Apoptotic protease activating factor 1 |
| APC | Adenomatous polyposis coli |
| APPROVe | Adenomatous Polyp Prevention on Vioxx |
| AT-LXA4 | Aspirin-triggered lipoxin A4 |
| ATL | Aspirin-triggered lipoxin |
| AT-PD1/AT-NPD1 | Aspirin-triggered protectin D1/Aspirin-triggered neuroprotectin D1 |
| AT-RvD | Aspirin-triggered D-series resolvin |
| AT-RvE | Aspirin-triggered E-series resolvin |
| Bad | Bcl-2-agonist of death |
| Bak | Bcl-2 homologous antagonist/killer |
| Bax | Bcl-2-like protein 4 |
| Bcl-2 | B-cell lymphoma 2 |
| BH3 | Bcl-2 homology 3 |
| Bid | BH3-interacting domain death agonist |
| Bim | Bcl-2-like protein 11 |
| CA | Carbonic anhydrase |
| CAI | Carbonic anhydrase inhibitor |
| cAMP | Cyclic adenosine monophosphate |
| cdk4 | Cyclin-dependent kinase 4 |
| cGMP | Cyclic guanosine monophosphate |
| CLASS | Celecoxib Long-Term Arthritis Safety Study |
| CO2 | Carbon dioxide |
| COX | Cyclooxygenase |
| COXIBs | COX-2 selective NSAIDs |
| DCP | Dichlorophenamide |
| DHA | Docosahexaenoic acid; (22:6, n-3) |
| DMC | 2,5-Dimethyl-celecoxib |
| DPA | Docosapentaenoic acid (22:5, n-3) |
| EGR-1 | Early growth response factor 1 |
| EPA | Eicosapentaenoic acid; (20:5, n-3) |
| ER | Endoplasmic reticulum |
| ERK | Extracellular-signal-regulated kinase |
| FAP | Familial adenomatous polyposis |
| GDP | Guanosine diphosphate |
| GI | Gastrointestinal |
| GSK-3β | Glycogen synthase kinase-3beta |
| GTP | Guanosine triphosphate |
| IL | Interleukin |
| IP3 | Inositol trisphosphate |
| IκB | I-kappa-B |
| JNK | c-Jun N-terminal kinase |
| LA | Linoleic acid; (18:2, n-6) |
| LOX | Lipoxygenase |
| LT | Leukotriene |
| LTA4 | Leukotriene A4 |
| LX | Lipoxin |
| MAPK | Mitogen-activated protein kinase |
| MaR | Maresin |
| MEK | MAPK/ERK kinase |
| MIF | migration inhibitory factor |
| mTOR | Mammalian target of rapamycin |
| mTORC1 | Mammalian target of rapamycin complex 1 |
| mTORC2 | Mammalian target of rapamycin complex 2 |
| NAG-1 | NSAID-activated gene |
| NF-κB | Nuclear factor kappa light-chain enhancer of activated B cells |
| NK cells | Natural killer cells |
| NSAIDs | Nonsteroidal anti-inflammatory drugs |
| PD1/NPD1 | Protectin D1/Neuroprotectin D1 |
| PDE | Phosphodiesterase |
| PDK-1 | phosphoinositide-dependent kinase-1 |
| PDs | Protectins |
| PG | Prostaglandin |
| PGI2 | Prostacyclin |
| PI3K | Phosphoinositide 3-kinase |
| PIP2 | Phosphatidylinositol (4,5)- bisphosphate |
| PIP3 | Phosphatidylinositol (3,4,5)- trisphosphate |
| PKG | Protein kinase G |
| PMNs | Polymorphonuclear leukocytes |
| PPAR | Peroxisome-proliferator-activated receptor |
| PUFAs | Polyunsaturated fatty acids |
| Puma | p53 upregulated modulator of apoptosis; Bcl-2-binding component 3 |
| RTX | retinoid X receptor |
| Rv | Resolvin |
| RvD | D-series resolvin |
| RvE | E-series resolvin |
| RvT | T-series resolvin |
| SPMs | Specialized pro-resolving mediators |
| TAM | Tumor-associated macrophages |
| Tcf-4 | Transcription factor 4 |
| TGF-β | Transforming growth factor-beta |
| TNF-α | Tumor necrosis factor-alpha |
| TXA2 | Thromboxane A2 |
| VEGF | Vascular endothelial growth factor |
| VIGOR | Vioxx Gastrointestinal Outcomes Research |
| Wnt/β-catenin | Wingless-related integration site/beta-catenin |